Cited 1 time in
Interferon Alpha-2a Reduces Early Erythema After Full-Thickness Skin Graft in the Pig
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Jun Sik | - |
| dc.contributor.author | Son, Daegu | - |
| dc.contributor.author | Choi, Tae Hyun | - |
| dc.contributor.author | Han, Kihwan | - |
| dc.contributor.author | Kim, Jun Hyung | - |
| dc.contributor.author | Cho, Hyun Mi | - |
| dc.contributor.author | Kim, Won Hee | - |
| dc.contributor.author | Kim, Sang-Hyon | - |
| dc.contributor.author | Kim, Nam Gyun | - |
| dc.contributor.author | Lee, Kyung Suk | - |
| dc.contributor.author | Hwang, O. Hyun | - |
| dc.contributor.author | Roh, Gu Seob | - |
| dc.contributor.author | Park, Jungbin | - |
| dc.date.accessioned | 2022-12-27T05:06:55Z | - |
| dc.date.available | 2022-12-27T05:06:55Z | - |
| dc.date.issued | 2009-10 | - |
| dc.identifier.issn | 1076-0512 | - |
| dc.identifier.issn | 1524-4725 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/26151 | - |
| dc.description.abstract | BACKGROUND Skin grafting is a commonly performed procedure, but studies of changes in the levels of cytokines after skin grafting have not been reported. OBJECTIVE We examined changes in cytokines and the degree of erythema after skin grafting in pigs in the control group. Interferon alpha (IFN-alpha) was injected to reduce erythema, and subsequent changes in cytokines and the degree of erythema were examined in the experimental group. METHODS Vascular endothelial growth factor (VEGF), thrombospondin-1 (TSP1), and CD31 were examined using Western blot analysis and immunohistochemistry. The degree of erythema was measured at 2, 4, and 8 weeks using a chromometer. RESULTS In the control group, VEGF increased at 2 weeks and decreased at 4 and 8 weeks. TSP1 increased over time. CD31 increased to 4 weeks and decreased at 8 weeks. In the experimental group, VEGF was lower at 2 weeks and higher at 8 weeks than in the control group, TSP1 was higher at 2 weeks and lower at 8 weeks, and CD31 was lower at 4 and 8 weeks. Erythema in the experimental group was lower than that in the control group at 2 and 8 weeks. CONCLUSION IFN-alpha may be one of the agents that reduces erythema by suppressing excessive revascularization. The authors have indicated no significant interest with commercial supporters. | - |
| dc.format.extent | 11 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | American Society for Dermatologic Surgery | - |
| dc.title | Interferon Alpha-2a Reduces Early Erythema After Full-Thickness Skin Graft in the Pig | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1111/j.1524-4725.2009.01267.x | - |
| dc.identifier.scopusid | 2-s2.0-70349686832 | - |
| dc.identifier.wosid | 000270397300009 | - |
| dc.identifier.bibliographicCitation | Dermatologic Surgery, v.35, no.10, pp 1514 - 1524 | - |
| dc.citation.title | Dermatologic Surgery | - |
| dc.citation.volume | 35 | - |
| dc.citation.number | 10 | - |
| dc.citation.startPage | 1514 | - |
| dc.citation.endPage | 1524 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Dermatology | - |
| dc.relation.journalResearchArea | Surgery | - |
| dc.relation.journalWebOfScienceCategory | Dermatology | - |
| dc.relation.journalWebOfScienceCategory | Surgery | - |
| dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
| dc.subject.keywordPlus | VEGF | - |
| dc.subject.keywordPlus | SURVIVAL | - |
| dc.subject.keywordPlus | COLOR | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
